Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSC

[News]

Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Ill.

More... (http://www.news-medical.net/news/20140515/Phase-I-study-reveals-abemaciclib-drug-shows-evidence-of-single-agent-activity-in-NSCLC-patients.aspx)